HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection

A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twen...

Full description

Saved in:
Bibliographic Details
Published inJournal of virology Vol. 91; no. 8
Main Authors Yue, Feng Yun, Cohen, Jared C, Ho, Mu, Rahman, A K M Nur-Ur, Liu, Jun, Mujib, Shariq, Saiyed, Aamir, Hundal, Sabrina, Khozin, Alexandra, Bonner, Phil, Liu, Daheng, Benko, Erika, Kovacs, Colin, Ostrowski, Mario
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 15.04.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4 T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4 T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8 T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8 cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines.
AbstractList A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4 + T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4 + T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8 + T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. IMPORTANCE A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8 + cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines.
A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4+ T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4+ T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8+ T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden.IMPORTANCE A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8+ cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines.
ABSTRACT A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4 + T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4 + T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8 + T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. IMPORTANCE A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8 + cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines.
A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4 T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4 T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8 T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8 cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines.
A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4+ T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN- gamma ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN- gamma responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN- gamma responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN- gamma , Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4+ T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN- gamma responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8+ T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. IMPORTANCE A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8+ cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN- gamma responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines.
Author Cohen, Jared C
Kovacs, Colin
Ostrowski, Mario
Khozin, Alexandra
Liu, Daheng
Hundal, Sabrina
Ho, Mu
Bonner, Phil
Benko, Erika
Rahman, A K M Nur-Ur
Saiyed, Aamir
Yue, Feng Yun
Liu, Jun
Mujib, Shariq
Author_xml – sequence: 1
  givenname: Feng Yun
  surname: Yue
  fullname: Yue, Feng Yun
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 2
  givenname: Jared C
  surname: Cohen
  fullname: Cohen, Jared C
  organization: Keenan Research Centre for Biomedical Science of Saint Michael's Hospital, Toronto, Ontario, Canada
– sequence: 3
  givenname: Mu
  surname: Ho
  fullname: Ho, Mu
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 4
  givenname: A K M Nur-Ur
  surname: Rahman
  fullname: Rahman, A K M Nur-Ur
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 5
  givenname: Jun
  surname: Liu
  fullname: Liu, Jun
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 6
  givenname: Shariq
  surname: Mujib
  fullname: Mujib, Shariq
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 7
  givenname: Aamir
  surname: Saiyed
  fullname: Saiyed, Aamir
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 8
  givenname: Sabrina
  surname: Hundal
  fullname: Hundal, Sabrina
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 9
  givenname: Alexandra
  surname: Khozin
  fullname: Khozin, Alexandra
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 10
  givenname: Phil
  surname: Bonner
  fullname: Bonner, Phil
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 11
  givenname: Daheng
  surname: Liu
  fullname: Liu, Daheng
  organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada
– sequence: 12
  givenname: Erika
  surname: Benko
  fullname: Benko, Erika
  organization: Maple Leaf Clinic, Toronto, Ontario, Canada
– sequence: 13
  givenname: Colin
  surname: Kovacs
  fullname: Kovacs, Colin
  organization: Maple Leaf Clinic, Toronto, Ontario, Canada
– sequence: 14
  givenname: Mario
  surname: Ostrowski
  fullname: Ostrowski, Mario
  email: mario.ostrowski@gmail.com
  organization: Keenan Research Centre for Biomedical Science of Saint Michael's Hospital, Toronto, Ontario, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28179527$$D View this record in MEDLINE/PubMed
BookMark eNqNkUFv1DAQhS1URLelN87IRw6k2HFiJxekZVW2i6pWou2Km-U449Yosbe2U7T8Cn4yXlqqcuM0mvGnN2_8DtCe8w4QekPJMaVl8-HLenVMypKxgvIXaEZJ2xR1Tas9NCN5XtSs-baPDmL8TgitKl69QvtlQ0Vbl2KGfp2u1sXlBrQ1VuNlUO7ndgT8qbgEHSBZd4O7KeFzn_BSjaPCK5cgGAjePUOu8AKGIeJ5ADyP0WurEvT4h023-Cv0k87N2gY15C5CuPc2RGwdPlFh2OJsIcsa0Ml69xq9NGqIcPRYD9H155OrxWlxdrFcLeZnha6oSIXqeKW7RhjFhSmZ6LuKN60ieaBAATGdIdD3PTG8JAqAs64UtBGMN2WtFWeH6OOD7mbqRug1uJT9yU2wowpb6ZWV_744eytv_L2smag5J1ng3aNA8HcTxCRHG3X-BuXAT1HSpt3tY6L6D5Rz3lJOREbfP6A6-BgDmCdHlMhd3jLnLf_kLenuirfPr3iC_wbMfgNGoaoO
CitedBy_id crossref_primary_10_20411_pai_v6i2_447
crossref_primary_10_4049_jimmunol_2000916
crossref_primary_10_1016_j_ebiom_2023_104538
crossref_primary_10_3389_fimmu_2021_734871
crossref_primary_10_3390_ijms24109047
crossref_primary_10_3389_fimmu_2018_02429
crossref_primary_10_1128_JVI_01480_18
crossref_primary_10_3389_fimmu_2020_00153
crossref_primary_10_3390_v11121104
crossref_primary_10_3390_vaccines12040441
crossref_primary_10_1016_j_immuni_2020_10_015
crossref_primary_10_1128_JVI_01832_18
crossref_primary_10_1172_jci_insight_142640
crossref_primary_10_3389_fimmu_2018_02443
crossref_primary_10_1080_07853890_2021_1995624
crossref_primary_10_1097_QAI_0000000000001747
crossref_primary_10_1172_jci_insight_93684
crossref_primary_10_1016_j_xcrm_2021_100205
crossref_primary_10_1007_s11904_019_00445_6
crossref_primary_10_1128_jvi_00509_22
crossref_primary_10_1097_QAD_0000000000002296
crossref_primary_10_1002_eji_202048976
crossref_primary_10_1097_QAI_0000000000001887
Cites_doi 10.1189/jlb.0208107
10.1016/j.immuni.2008.10.010
10.1016/S0022-1759(00)00191-5
10.1093/cid/cis188
10.1097/01.COH.0000209582.82328.b8
10.1186/1479-5876-1-14
10.1016/j.tim.2015.01.013
10.1016/j.coviro.2013.07.006
10.1073/pnas.1406663111
10.1073/pnas.0611244104
10.1073/pnas.95.15.8869
10.1038/ni845
10.1086/428777
10.1073/pnas.1414926112
10.1186/1742-4690-10-11
10.1126/scitranslmed.3003165
10.1073/pnas.1609057113
10.1101/cshperspect.a007054
10.1093/ofid/ofv138
10.1097/QAI.0b013e3182a1bc81
10.1016/j.cell.2013.09.020
10.1097/COH.0b013e32835d6e1c
10.1038/nm880
10.1016/S0140-6736(04)15735-8
10.1038/nri3839
10.1146/annurev-pathol-011110-130254
10.1128/JVI.01472-10
10.1101/cshperspect.a006916
10.1097/QAD.0000000000000508
10.1038/ncomms9495
10.1101/cshperspect.a007096
10.1128/jcm.32.3.732-739.1994
10.1073/pnas.96.26.15109
ContentType Journal Article
Copyright Copyright © 2017 American Society for Microbiology.
Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology
Copyright_xml – notice: Copyright © 2017 American Society for Microbiology.
– notice: Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7T5
7U9
H94
5PM
DOI 10.1128/JVI.02233-16
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
DatabaseTitleList
MEDLINE - Academic
CrossRef
MEDLINE
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Granzyme B and HIV Reservoirs
EISSN 1098-5514
Editor Silvestri, Guido
Editor_xml – sequence: 1
  givenname: Guido
  surname: Silvestri
  fullname: Silvestri, Guido
ExternalDocumentID 10_1128_JVI_02233_16
28179527
Genre Journal Article
GrantInformation_xml – fundername: CIHR
  grantid: HOP-10754
– fundername: Ontario HIV Treatment Network (OHTN)
  grantid: AHRC G769
– fundername: Gouvernement du Canada | Canadian Institutes of Health Research (CIHR)
  grantid: HOP-10754
GroupedDBID ---
-~X
0R~
18M
29L
2WC
39C
4.4
53G
5GY
5RE
5VS
85S
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
N9A
NPM
O9-
OK1
P2P
RHF
RHI
RNS
RPM
RSF
TR2
UCJ
UPT
W2D
W8F
WH7
WOQ
YQT
~02
~KM
AAYXX
CITATION
7X8
7T5
7U9
H94
5PM
ID FETCH-LOGICAL-c417t-ab64cb87fa67f237db4689a07faaeae0fbf0eddd0f620aee63b2718736825ca63
IEDL.DBID RPM
ISSN 0022-538X
IngestDate Tue Sep 17 21:24:17 EDT 2024
Wed Jul 24 17:49:57 EDT 2024
Fri Aug 16 23:51:17 EDT 2024
Thu Sep 12 17:16:47 EDT 2024
Sat Sep 28 08:33:38 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords acute
granzyme B
viral reservoirs
early HIV
T cell
cure research
ELISpot
IFN-γ
HIV
acute HIV
human immunodeficiency virus
CTL
reservoir
cytotoxic
early
Language English
License Copyright © 2017 American Society for Microbiology.
All Rights Reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c417t-ab64cb87fa67f237db4689a07faaeae0fbf0eddd0f620aee63b2718736825ca63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Yue FY, Cohen JC, Ho M, Rahman AKMN, Liu J, Mujib S, Saiyed A, Hundal S, Khozin A, Bonner P, Liu D, Benko E, Kovacs C, Ostrowski M. 2017. HIV-specific granzyme B-secreting but not gamma interferon-secreting T cells are associated with reduced viral reservoirs in early HIV infection. J Virol 91:e02233-16. https://doi.org/10.1128/JVI.02233-16.
F.Y.Y. and J.C.C. contributed equally to this article.
OpenAccessLink https://jvi.asm.org/content/jvi/91/8/e02233-16.full.pdf
PMID 28179527
PQID 1866691607
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5375660
proquest_miscellaneous_1891873374
proquest_miscellaneous_1866691607
crossref_primary_10_1128_JVI_02233_16
pubmed_primary_28179527
PublicationCentury 2000
PublicationDate 2017-04-15
PublicationDateYYYYMMDD 2017-04-15
PublicationDate_xml – month: 04
  year: 2017
  text: 2017-04-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2017
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_20_2
e_1_3_2_21_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_25_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
e_1_3_2_14_2
References_xml – ident: e_1_3_2_24_2
  doi: 10.1189/jlb.0208107
– ident: e_1_3_2_15_2
  doi: 10.1016/j.immuni.2008.10.010
– ident: e_1_3_2_30_2
  doi: 10.1016/S0022-1759(00)00191-5
– ident: e_1_3_2_12_2
  doi: 10.1093/cid/cis188
– ident: e_1_3_2_27_2
  doi: 10.1097/01.COH.0000209582.82328.b8
– ident: e_1_3_2_31_2
  doi: 10.1186/1479-5876-1-14
– ident: e_1_3_2_9_2
  doi: 10.1016/j.tim.2015.01.013
– ident: e_1_3_2_7_2
  doi: 10.1016/j.coviro.2013.07.006
– ident: e_1_3_2_28_2
  doi: 10.1073/pnas.1406663111
– ident: e_1_3_2_16_2
  doi: 10.1073/pnas.0611244104
– ident: e_1_3_2_2_2
  doi: 10.1073/pnas.95.15.8869
– ident: e_1_3_2_18_2
  doi: 10.1038/ni845
– ident: e_1_3_2_5_2
  doi: 10.1086/428777
– ident: e_1_3_2_26_2
  doi: 10.1073/pnas.1414926112
– ident: e_1_3_2_3_2
  doi: 10.1186/1742-4690-10-11
– ident: e_1_3_2_29_2
  doi: 10.1126/scitranslmed.3003165
– ident: e_1_3_2_33_2
  doi: 10.1073/pnas.1609057113
– ident: e_1_3_2_23_2
  doi: 10.1101/cshperspect.a007054
– ident: e_1_3_2_19_2
  doi: 10.1093/ofid/ofv138
– ident: e_1_3_2_11_2
  doi: 10.1097/QAI.0b013e3182a1bc81
– ident: e_1_3_2_8_2
  doi: 10.1016/j.cell.2013.09.020
– ident: e_1_3_2_22_2
  doi: 10.1097/COH.0b013e32835d6e1c
– ident: e_1_3_2_4_2
  doi: 10.1038/nm880
– ident: e_1_3_2_13_2
  doi: 10.1016/S0140-6736(04)15735-8
– ident: e_1_3_2_17_2
  doi: 10.1038/nri3839
– ident: e_1_3_2_6_2
  doi: 10.1146/annurev-pathol-011110-130254
– ident: e_1_3_2_20_2
  doi: 10.1128/JVI.01472-10
– ident: e_1_3_2_32_2
  doi: 10.1101/cshperspect.a006916
– ident: e_1_3_2_21_2
  doi: 10.1097/QAD.0000000000000508
– ident: e_1_3_2_14_2
  doi: 10.1038/ncomms9495
– ident: e_1_3_2_10_2
  doi: 10.1101/cshperspect.a007096
– ident: e_1_3_2_34_2
  doi: 10.1128/jcm.32.3.732-739.1994
– ident: e_1_3_2_25_2
  doi: 10.1073/pnas.96.26.15109
SSID ssj0014464
Score 2.4187756
Snippet A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral...
ABSTRACT A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
SubjectTerms Adult
Antiviral Agents
CD4-Positive T-Lymphocytes - virology
CD8-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - metabolism
CD8-Positive T-Lymphocytes - virology
Cytotoxins - metabolism
Disease Reservoirs - virology
Granzymes - metabolism
HIV Infections - immunology
Human immunodeficiency virus 1
Humans
Interferon-gamma - metabolism
Lentivirus
Male
Middle Aged
Pathogenesis and Immunity
Retroviridae
Young Adult
Title HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection
URI https://www.ncbi.nlm.nih.gov/pubmed/28179527
https://search.proquest.com/docview/1866691607
https://search.proquest.com/docview/1891873374
https://pubmed.ncbi.nlm.nih.gov/PMC5375660
Volume 91
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVtYbCXsXZf2bqhwfaoxJYsyX7cwtq0sDK2NuTNSLZEDbFcEmfQ_Yr95F3JUUk72MMeLV9bwufaulc6PhehD4lWSkCaQIwwjEAEnhANUTHhNjNGpEJJG1i-F2J2lZ0v-GIP8fgvTCDtV7oZu2U7ds114FbetNUk8sQm375OOZMQhSSTfbQvGYsp-nbrAPKbLEqEw9u8iGx3mk_O52djaGaMpL50Ec3BG7mvJ7M7Jf0VZz6kS-7MPydP0ZNt4Ig_DQM8RHvGHaFHQynJ22fo9-xsTkIxedtU-BRmoF-3rcGfyQ8fF3puM9abHl90PT5VbatwWAq0ZtW5HZNLPDXL5Rp6MTgCZ2rsF2vxdy_yCgfzBkaHPWNv9bNrVmvcOBxkkjEMAW47kLvcc3R18uVyOiPbagukylLZE6VFVulcWsDOUiZrnYm8UAk0KKNMYrVNTF3XiRU0UQAk0xQmNskEJJmVEuwFOnCdM68Qhu9EqjgXKisgvaFK0ULVvFYCzAzkeCP0MT7w8mYQ1ShDMkLzEjAqA0ZlKkbofUSjBK_3WxnKmW6zLr1Mnyi8ON6_bAo_PCazEXo5IHjXW4R-hOQ9bO8MvOr2_TPgjEF9e-t8r__7yjfoMfWxgReM5MfooF9tzFuIbHr9LnjyH4An-c0
link.rule.ids 230,315,733,786,790,891,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIQQvfH-UTyPBo9PEiZ3kESq2dmwVgq7qW2QnjohokqlNkba_gj-Zs1NP3ZCQ4DH2JbF159yd_cvvAN75SkqBaQLVQocUI3CfKoyKKS8jrUUgZFxalO9UjE-jowVf7AF3_8JY0H6uKq9Z1l5TfbfYyrM6Hzqc2PDLyYiHMUYh_vAG3MT1yrhL0reHB5jhRI4kHPsXDu_OkuHRfOJhcxjSwBQvYgnaIzcVZXad0h-R5nXA5I4HOrgHczf2Hnjyw9t0yssvrtE6_vPk7sPdbUxKPvTdD2BPNw_hVl-l8vwR_BpP5tTWqS-rnByic7s4rzX5SL-ZkNPAponadGTaduRQ1rUkdpex1Ku22RGZkZFeLtf4Fk2cTeiCmH1g8tXwx-LFvMJpEwMGXP1sq9WaVA2xDMwEh4CP7XFjzWM4Pfg0G43ptpADzaMg7qhUIspVEpdoFiUL40JFIkmljw1SS-2XqvR1URR-KZgv0UZCxdBnxqFA5eZShE9gv2kb_QwIfoICybmQUYqZE5OSpbLghRQopjF9HMB7p8nsrOfryGyew5IMlZ9Z5WeBGMBbp-YMF5Q5JZGNbjfrzDAAitTw7v1NJjXDC-NoAE9707h8m7OpAcRXjOZSwBB6X-1BU7DE3lvVP__vO9_A7fHs5Dg7nkw_v4A7zIQghpeSv4T9brXRrzCA6tRru1x-A6SIG9I
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgCMQL90u5GgkenYudOMkjFLp2QDXBVlW8RHZia9GapGpTpO1X8JM5duqpGxIPe4x9Etvy5_gc-9N3EHofSCE4hAlEccUIeOABkeAVk1hHSvGQi0Rblu-Uj4-jg3k830n1ZUn7hay8ZlF7TXViuZXLuvAdT8w__D6MWQJeSOAvS-3fRLdgzdLEBerbCwSIciInFA71c8d5p6l_MJt4UMwYCU0CI5oCJmOTVWZ3Y_rH27xKmtzZhUb30S_X_558cuptOukV51ekHa81wAfo3tY3xR97k4fohmoeodt9tsqzx-jPeDIjNl-9rgq8D5vc-Vmt8Cfy07iehj6N5abD07bD-6KuBbanjVqt2mbH5AgP1WKxhlYUdthQJTbnwfiH0ZGFh1kFQ8eGFLj63VarNa4abJWYMXQBPtvzx5on6Hj05Wg4JtuEDqSIwqQjQvKokGmiAR6asqSUEU8zEUCBUEIFWupAlWUZaE4DAVhhksLemTAOcWwhOHuK9pq2Uc8Rhl9RKOKYiyiDCIoKQTNRxqXgYKYgjBygD24282Wv25HbeIemOQAgtwDIQz5A79xU57CwzG2JaFS7WedGCZBnRn_vfzaZ6R5LogF61sPjojWHqwFKLgHnwsAIe1-uAThYge_t9L-49ptv0Z3Dz6P822T69SW6S40nYuQp41dor1tt1Gvwozr5xq6Yv3lnHlI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV-Specific+Granzyme+B-Secreting+but+Not+Gamma+Interferon-Secreting+T+Cells+Are+Associated+with+Reduced+Viral+Reservoirs+in+Early+HIV+Infection&rft.jtitle=Journal+of+virology&rft.au=Yue%2C+Feng+Yun&rft.au=Cohen%2C+Jared+C&rft.au=Ho%2C+Mu&rft.au=Rahman%2C+A+K+M+Nur-Ur&rft.date=2017-04-15&rft.eissn=1098-5514&rft.volume=91&rft.issue=8&rft_id=info:doi/10.1128%2FJVI.02233-16&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon